Olezarsen (Tryngolza) for severe hypertriglyceridemia.

Abstract

The FDA has approved olezarsen (Tryngolza – Ionis), a subcutaneously injected apolipoprotein C-III (apoC-III)-directed antisense oligonucleotide, to reduce triglyceride levels and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. Olezarsen and the apoC-III-directed small interfering RNA plozasiran (Redemplo) were approved earlier to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS).